Non-Small Cell Lung Cancer Market: Trends, Forecast, and Competitive Landscape 2023 -2030

This Non-Small Cell Lung Cancer Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. The market insights covered in Electric Enclosure report simplifies managing marketing of goods and services effectively.

Data Bridge Market Research analyses that the non-small cell lung cancer market which is USD 26948.36 million in 2022, is expected to reach USD 76334.72 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030.

Download Sample PDF Copy of this Report to understand structure of the complete report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-small-cell-lung-cancer-market

Market Overview:

According to data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH), approximately 85% of lung cancer cases in the United States are NSCLC. Squamous cell carcinoma accounted for 30% of the cases, adenocarcinoma accounted for 40%, and large-cell carcinoma accounted for 15%. Furthermore, all other country-based registries reported nearly the same percentage of NSCLC and its major subtypes.

Some of the major players operating in the Non-Small Cell Lung Cancer Market are

Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), CLOVIS ONCOLOGY (U.S.), Johnson & Johnson Private Limited (U.S.)

Global Non-Small Cell Lung Cancer Market Scope

The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Pulmonary Neuroendocrine Tumours
Mediastina Tumours
Mesothelioma
Chest Wall Tumours
Type

Adenocarcinomas
Squamous Cell Carcinoma
Large Cell Carcinomas
Others
Molecule Type

Small Molecules
Biologics
Drug Class

Alkylating Agents
Antimetabolites
EGFR Inhibitors
Mitotic Inhibitors
Multi-kinase Inhibitors
Others
Treatment Type

Chemotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Others
Diagnosis

CT Scan
X-Rays
Sputum Cytology
Bronchoscopy
Laboratory Tests
Thoracoscopy
Others
Therapy Type

Single Drug Therapy
Combination Therapy
End User

Hospitals
Homecare
Specialty Clinics
Others
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online
Others
Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-non-small-cell-lung-cancer-market

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Non-Small Cell Lung Cancer Market

Part 04: Global Non-Small Cell Lung Cancer Market Sizing

Part 05: Global Non-Small Cell Lung Cancer Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Browse Trending Reports:

https://trendmarketinsights.blogspot.com/2024/11/medical-imaging-market-trends-forecast_27.html

https://trendmarketinsights.blogspot.com/2024/11/cold-plunge-pools-market-trends.html

https://trendmarketinsights.blogspot.com/2024/11/circulating-tumor-dna-ctdna-market.html

Data Bridge Market Research

US: +1 888 387 2818

United Kingdom: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: - sopan.gedam@databridgemarketresearch.com

An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.

Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

This release was published on openPR.